BioSyent Inc. (OTCMKTS:BIOYF – Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 1,200 shares, a decrease of 33.3% from the August 31st total of 1,800 shares. Based on an average daily volume of 600 shares, the short-interest ratio is currently 2.0 days.
BioSyent Stock Performance
Shares of BIOYF stock remained flat at $8.19 during mid-day trading on Friday. 294 shares of the company’s stock traded hands, compared to its average volume of 2,153. The stock’s 50-day moving average price is $7.65 and its two-hundred day moving average price is $7.03. BioSyent has a 1-year low of $5.65 and a 1-year high of $8.56.
BioSyent Increases Dividend
The company also recently disclosed a dividend, which was paid on Sunday, September 15th. Stockholders of record on Thursday, September 5th were paid a dividend of $0.0334 per share. This is a boost from BioSyent’s previous dividend of $0.03. The ex-dividend date was Wednesday, September 4th. This represents a dividend yield of 1.72%.
About BioSyent
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
- Five stocks we like better than BioSyent
- Using the MarketBeat Dividend Yield Calculator
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What is a Low P/E Ratio and What Does it Tell Investors?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.